The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics

    Research output: Contribution to journalArticle

    Published

    Standard

    The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe) : design and baseline characteristics. / Jones, Roy W; Kivipelto, Miia; Feldman, Howard; Sparks, Larry; Doody, Rachelle; Waters, David D; Hey-Hadavi, Judith; Breazna, Andrei; Schindler, Rachel J; Ramos, Harry; LEADe investigators ; Passmore, Peter.

    In: Alzheimer's & dementia : the journal of the Alzheimer's Association, Vol. 4, No. 2, 03.2008, p. 145-53.

    Research output: Contribution to journalArticle

    Harvard

    Jones, RW, Kivipelto, M, Feldman, H, Sparks, L, Doody, R, Waters, DD, Hey-Hadavi, J, Breazna, A, Schindler, RJ, Ramos, H, LEADe investigators & Passmore, P 2008, 'The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics' Alzheimer's & dementia : the journal of the Alzheimer's Association, vol. 4, no. 2, pp. 145-53. https://doi.org/10.1016/j.jalz.2008.02.001

    APA

    Vancouver

    Author

    Jones, Roy W ; Kivipelto, Miia ; Feldman, Howard ; Sparks, Larry ; Doody, Rachelle ; Waters, David D ; Hey-Hadavi, Judith ; Breazna, Andrei ; Schindler, Rachel J ; Ramos, Harry ; LEADe investigators ; Passmore, Peter. / The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe) : design and baseline characteristics. In: Alzheimer's & dementia : the journal of the Alzheimer's Association. 2008 ; Vol. 4, No. 2. pp. 145-53.

    Bibtex

    @article{13e78021f724442bbf40a54555f76141,
    title = "The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics",
    abstract = "Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).",
    author = "Jones, {Roy W} and Miia Kivipelto and Howard Feldman and Larry Sparks and Rachelle Doody and Waters, {David D} and Judith Hey-Hadavi and Andrei Breazna and Schindler, {Rachel J} and Harry Ramos and {LEADe investigators} and Peter Passmore",
    year = "2008",
    month = "3",
    doi = "10.1016/j.jalz.2008.02.001",
    language = "English",
    volume = "4",
    pages = "145--53",
    journal = "Alzheimer's & dementia : the journal of the Alzheimer's Association",
    issn = "1552-5279",
    number = "2",

    }

    RIS

    TY - JOUR

    T1 - The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe)

    T2 - Alzheimer's & dementia : the journal of the Alzheimer's Association

    AU - Jones, Roy W

    AU - Kivipelto, Miia

    AU - Feldman, Howard

    AU - Sparks, Larry

    AU - Doody, Rachelle

    AU - Waters, David D

    AU - Hey-Hadavi, Judith

    AU - Breazna, Andrei

    AU - Schindler, Rachel J

    AU - Ramos, Harry

    AU - LEADe investigators

    AU - Passmore, Peter

    PY - 2008/3

    Y1 - 2008/3

    N2 - Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).

    AB - Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).

    U2 - 10.1016/j.jalz.2008.02.001

    DO - 10.1016/j.jalz.2008.02.001

    M3 - Article

    VL - 4

    SP - 145

    EP - 153

    JO - Alzheimer's & dementia : the journal of the Alzheimer's Association

    JF - Alzheimer's & dementia : the journal of the Alzheimer's Association

    SN - 1552-5279

    IS - 2

    ER -

    Download

    Download as: RIS